Parsons Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Parsons Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-31,831	Closed	-$1.47M	–	344
2016 Q3	$1.47M	Sell	31,831 -638	-2%	-$33.3K	0.2%	123
2016 Q2	$1.63M	Sell	32,469 -40	-0.1%	-$2.13K	0.22%	116
2016 Q1	$1.74M	Sell	32,509 -153	-0.5%	-$8.98K	0.24%	110
2015 Q4	$2.14M	Sell	32,662 -35	-0.1%	-$2.16K	0.3%	86
2015 Q3	$1.85M	Sell	32,697 -125	-0.4%	-$8.11K	0.27%	99
2015 Q2	$1.94M	Sell	32,822 -285	-0.9%	-$17.6K	0.26%	102
2015 Q1	$2.06M	Sell	33,107 -2,910	-8%	-$169K	0.29%	92
2014 Q4	$2.07M	Hold	36,017	–	–	0.27%	99
2014 Q3	$1.94M	Sell	36,017 -468	-1%	-$24.8K	0.27%	97
2014 Q2	$1.91M	Sell	36,485 -477	-1%	-$24.4K	0.26%	99
2014 Q1	$1.95M	Sell	36,962 -135	-0.4%	-$6.24K	0.28%	96
2013 Q4	$1.49M	Buy	37,097 +1,700	+5%	+$66.9K	0.22%	125
2013 Q3	$1.34M	Buy	35,397 +2,642	+8%	+$103K	0.22%	128
2013 Q2	$1.28M	Buy	+32,755	New	+$1.28M	0.22%	127

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Parsons Capital Management's TEVA Position: Q4 2016 in Review

Parsons Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 31,831 shares — an estimated $1.47M sold.

Parsons Capital Management first reported a position in TEVA in Q2 2013 and held it in 14 quarters. The position peaked at $2.14M in Q4 2015. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Parsons Capital Management reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Parsons Capital Management sold 31,831 Teva Pharmaceuticals shares in Q4 2016, an estimated $1.47M.
Parsons Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 14 quarters.
Parsons Capital Management's Teva Pharmaceuticals position peaked at $2.14M in Q4 2015.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Parsons Capital Management's 13F filing for Q4 2016, filed 2 Feb 2017.